

# Supplementary Materials: Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2–8) in Normal and Cancerous Breast and Prostate Cells


Dong Gui Hu, Ross A. McKinnon, Julie-Ann Hulin, Peter I. Mackenzie and Robyn Meech

supplemental Figure 1



Figure Supplementary 1: Chromatogram of sequencing shows splicing of exon 1b of the AR gene between exon 1 and exon 2 in a clone that was derived from breast cancer MDA-MB-453 cells in RT-PCR designed to amplify the full-length cDNA of the AR gene

**Figure S1.** Chromatogram of sequencing shows splicing of exon 1b of the AR gene between exon 1 and exon 2 in a clone that was derived from breast cancer MDA-MB-453 cells in RT-PCR designed to amplify the full-length cDNA of the AR gene. The nucleotides of A, C, G, T in the chromatogram are in green, blue, black, and red, respectively.



**Figure S2.** The anti-AR antibody (N20) detected low levels of proteins with a molecular weight consistent with type 3 AR proteins in MDA-MB-231 cells (**A**) and LNCaP cells (**B**) in western blotting assays with a 10-minute exposure time. (**A**) MDA-MB-231 cells were transfected with a pcDNA3 vector expressing no ectopic protein (pcDNA3), wild-type AR (AR WT), AR-V7, type 3a AR, or type 3b AR; (**B**) LNCaP cells were transfected with a pcDNA3 vector expressing no ectopic protein (pcDNA3) or type 3a AR. Cell lysates were prepared from transfected cells 48 hours post-transfection and 30 µg of proteins were subjected to Western blotting assays with an antibody recognizing androgen receptor (AR) (N20) or beta actin as described in Methods. Of note, a 10-minute exposure time was applied in order to show low levels of endogenously expressed type 3 AR proteins in MDA-MB-231 (**A**) and LNCaP (**B**) cells.

**Table S1.** Primers used for real-time quantitative PCR.

Genes	Forward Primer (5'–3')	Reverse Primer (5'–3')	PCR Products Size (bp)
<i>BCHE</i>	ACGGTGGGCAAATTTTGCAA	CATTGTTGAGCACGTAAGTTT	149
<i>COL12A1</i>	CAGAATAACGGTGGACCCTA	GTTATTGTCACCACATACTC	120
<i>EFNB2</i>	ACAAATGGAAGAAGTTCGAC	GAAGATGATGCATCCTGAAG	150
<i>EPHA3</i>	AGGTGTGCAATGTCATGGAC	ACCAATGGAATGCTATTGCA	130
<i>GRIN3A</i>	TGGTGAGCACATAGTATACA	ACACGTTTGGTCTTGAAATG	150
<i>GSTA1</i>	ACCTCTATGGGAAAAGACATA	TGGCATCTTTTCCTCAGGT	120
<i>LRRTM3</i>	CCCTAAGCCAAAGCAAAAGA	AGCATTGTCAGTAAGACAGT	130
<i>LRRN1</i>	TGCCACGGACCTGTGCACAT	GTCTTGGTTGAGCTGTGTAG	130
<i>PSMD5</i>	TCACCCTGATGATTCTGTA	ATAGATTCTCTCCACCAATG	140
<i>PCG-AS</i>	GCCAATCCGTATATTGTAAA	TGTAGGCATGATAGATAACA	140
<i>PCG3</i>	TGGTCTGAAGTTCCAGAAAAG	GCTTTGGAGGCAGCATTCT	140
<i>PCGEM1</i>	CCGTAACCTGTGTCTGCAACTTCCT	CATGAAGTGTCAAATGCACCAAGCC	145
<i>SLITRK3</i>	CCTGGCGCTCCAGTTTAGGA	ATCCTAGAGCAATTGTGCTT	130
<i>ST8SIA4</i>	TTCAATCTTCCAGCACAAATG	AGGCTTAAAACTGCTCTTGA	130
<i>TOX3</i>	AGACTTCATTACCTGATAAC	ATTTCGAATTCCTCGTCCCC	140